Wire · opportunities
Roundup: Rona Therapeutics Enters Global License Agreement for ALK7-targeting RNAi ...
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 14 October 2026 · Fusion42 review
Roche has secured an exclusive global license for Rona Therapeutics' RNAi candidate targeting ALK7 for obesity treatment, with potential payments exceeding $1 billion. Pfizer has partnered with Enodia Therapeutics to develop Sec61 inhibitors with a deal potentially worth over $500 million.
This Wire brief sits within Fusion42's coverage of Biotech, and 4 sources have reported it between 13 Oct 2026 and 16 Oct 2026.
◆ ◆ The Wire takeaway
You can expect new obesity treatments that act directly on fat cells instead of appetite, opening novel therapeutic opportunities. Targeting proteins early in disease pathways now gains commercial validation, signalling new niches for drug discovery.
◆ Coverage
4 sources · first reported 13 Oct 2026 · latest 16 Oct 2026
◆ Related on Wire
◆ Topics